Johnson Johnson Story

JNJ -- USA Stock  

USD 140.09  0.14  0.1%

Macroaxis News
  
By Vlad Skutelnik
This report is for traders who are contemplating to exit Johnson Johnson. I will concentrate on why it could still be a good year for Johnson Johnson traders. Here I will also examine some technical and fundamental indicators drivers that the stock investors should consider in March. We found thirty-eight available reported financial drivers for Johnson Johnson which can be compared to its competitors. To make sure the equity is not overpriced, please check out all Johnson Johnson fundamentals including its Total Debt, Market Capitalization and the relationship between Gross Profit and Short Ratio . Given that Johnson Johnson has Price to Earning of 23.62X, we strongly advise you confirm Johnson Johnson regular market performance to make sure the company can sustain itself down the road. Use Johnson Johnson to enhance returns of your portfolios. The stock experiences normal upward fluctuation. Check odds of Johnson Johnson to be traded at $139.02 in 30 days.
Will Johnson Johnson continue to be wobbly?

The company is overvalued at 126.58 per share with modest projections ahead. The company retains Market Volatility (i.e. Beta) of 1.0417 which attests that Johnson Johnson returns are very sensitive to returns on the market. as market goes up or down, Johnson Johnson is expected to follow. Even though it is essential to pay attention to Johnson Johnson current price history, it is always good to be careful when utilizing equity current price movements. Macroaxis philosophy towards determining future performance of any stock is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Johnson Johnson exposes twenty-one different technical indicators which can help you to evaluate its performance. Johnson Johnson has expected return of -0.2389%. Please be advised to check out Johnson Johnson Information Ratio as well as the relationship between Potential Upside and Kurtosis to decide if Johnson Johnson past performance will be repeated at some point in the near future.


Johnson Johnson has Return on Asset of 8.4 % which means that on every $100 spent on asset it made $8.4 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 24.52 % implying that it generated $24.52 on every 100 dollars invested. The recent Johnson Johnson price drops may raise some interest from investors. The Stock closed today at a share price of 131.54 on 4436718.000 in trading volume. The company executives were unable to exploit market volatilities in January. However, diversifying your overall positions with Johnson Johnson can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 2.4465. The current volatility is consistent with the ongoing market swings in January 2019 as well as with Johnson Johnson unsystematic, company specific events. Johnson Johnson defends 6.6 z score. Johnson Johnson is selling at 132.40. That is 0.27 percent up. Started trading at 132.40. Johnson Johnson Net Cash Flow from Operations is fairly stable at the moment. Also, Johnson Johnson Consolidated Income is fairly stable at the moment.

 2013 2014 2016 2018 2019 (projected)
Johnson Johnson Cost of Revenue 22,746,000,000  21,536,000,000  21,685,000,000  19,516,500,000  17,601,526,316 
Johnson Johnson Consolidated Income 16,323,000,000  15,409,000,000  16,540,000,000  14,886,000,000  12,576,026,316 

To sum up, we believe that at this point Johnson Johnson is not too risky with low probability of distress within the next 2 years. Our ongoing buy vs. sell advice on the organization is Hold.

Johnson Johnson Valuation

Enterprise Value

Johnson Johnson exotic insider transaction detected

Johnson Johnson insider trading alert for general transaction of common by Weldon William C, ChairmanCEO, on June 18, 2019. This event was filed by Johnson Johnson with SEC on 2006-02-15. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

About Contributor

Vlad Skutelnik
   Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered as solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Johnson Johnson. Please refer to our Terms of Use for any information regarding our disclosure principles.

Story Momentum

This article from Macroaxis published on 11 of February contributed to the next trading period price escalation.The trading delta at closing time to the next next day price was 1.64% . The trading delta at closing time when the story was published to current price is 6.48% .

Similar stores for Johnson Johnson

a day ago at MacroaxisInsider 
Johnson Johnson exotic insider transaction detected
Macroaxis News
Filed transaction by Johnson Johnson director. Unconventional Insider trading
few days ago at MacroaxisInsider 
Bona fide gift to Deyo Russell C of 407 shares of Johnson Johnson subject to Section 16
Macroaxis News
Filed transaction by Johnson Johnson officer. Exempt bona fide gift subject to Rule 16b-3
over a week ago at MacroaxisInsider 
Purchase by Marillyn Hewson of 3000 shares of Johnson Johnson
Macroaxis News
Filed transaction by Johnson Johnson director. General open market or private purchase of non-derivative or derivative security
over a week ago at www.barrons.com 
How the Opioid Litigation Against Drug Companies Could Play Out. - Barrons
Barrons News
How the Opioid Litigation Against Drug Companies Could Play Out. BarronsStocks of Teva and Johnson Johnson recently took hits on news from an opioid case in Oklahoma. Investors are trying to handicap the potential exposure from ...
over two weeks ago at MacroaxisInsider 
Acquisition by Johns Michael M E of 1523 shares of Johnson Johnson subject to Rule 16b-3
Macroaxis News
Filed transaction by Johnson Johnson director. Grant, award or other acquisition pursuant to Rule 16b-3
over two weeks ago at MacroaxisInsider 
Acquisition or disposition of Johnson Johnson securities by Heisen Joann Heffernan
Macroaxis News
Filed transaction by Johnson Johnson officer. Acquisition or disposition under rule 16b-3
over three weeks ago at MacroaxisInsider 
Johnson Johnson exotic insider transaction detected
Macroaxis News
Filed transaction by Johnson Johnson officer. Unconventional Insider trading
over three weeks ago at Macroaxis 
Johnson Johnson is -0.49 percent down
Macroaxis News
In this review I will examine Johnson Johnson. I will concentrate on why it could still be a good year for Johnson Johnson traders. On 24 of May the company is traded for 139.11. Johnson Johnson has historical hype elasticity of 0.04. The entity is estimated to increase in value after the next headline with price going to jump to 139.15. The average volatility of media hype impact on Johnson Johnson stock price is about 67.0%. The price escalation on the next news is projected to be 0.03% where as daily expected return is currently at 0.04%. The volatility of related hype on Johnson Johnson is about 1340.0% with expected price after next announcement by competition of 139.11. Considering 30-days investment horizon, the next estimated press release will be in about 8 days. This firm dividends can provide a clue to current valuation of the stock. Johnson Johnson one year expected dividend income is about $1.72 per share.
over a month ago at www.investors.com 
Biotech Stock MeiraGTx Could Be Takeover Candidate For Gene Therapy Drugs Analyst - Investors Business Daily
news
Biotech Stock MeiraGTx Could Be Takeover Candidate For Gene Therapy Drugs Analyst Investors Business DailyDow Jones component Johnson Johnson could buy out biotech stock MeiraGTx for its efforts in gene therapy, an analyst suggested Friday.
over a month ago at www.thestreet.com 
Johnson Johnson Still Has Multiple Growth Drivers to Power Its Stock - TheStreet.com
Thestreet News
Johnson Johnson Still Has Multiple Growth Drivers to Power Its Stock TheStreet.comLitigation risks related to the companys baby powder are outweighed by JandJs other growth areas....JNJ.
over three weeks ago at MacroaxisInsider 
Acquisition by Cosgrove Stephen J of 4682 shares of Johnson Johnson subject to Rule 16b-3
Macroaxis News
Filed transaction by Johnson Johnson officer. Grant, award or other acquisition pursuant to Rule 16b-3
over two months ago at thewellesleysnews.com 
Securities Analyst Recommendations Aflac Incorporated , Johnson Johnson - Analyst Journal
news
Securities Analyst Recommendations Aflac Incorporated , Johnson Johnson Analyst JournalAflac Incorporated tinted gains of 0.45 percent to US49. The volume of 3.1 Million shares climbed down over an trading activity of 3.34 ...

Compare Johnson Johnson

Compare Johnson Johnson To Peers

Return On Asset

Return On Asset Comparative Analysis

  Return On Asset 
      Johnson Johnson Comparables 
Johnson Johnson is rated third overall in return on asset category among related companies. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Please also check Johnson Johnson Hype Analysis, Johnson Johnson Correlation and Johnson Johnson Performance. Please also try Crypto Portfolio Optimizer module to optimize portfolio of digital coins and token across multiple currency and exchanges.
Search macroaxis.com